secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001140361-23-038803
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M
--------------------------------------------------------------------------------

- Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.
- Adjusted EBITDA $6.4M vs. -$6.3M YoY; net loss narrowed to $6.4M from $13.8M; adjusted net loss $3.6M.
- FY2023 revenue guidance raised to at least $240M (from $220M); FY2024 raised to $275M; FY2025 to $325M+.
- Nonrecurring IT disruption charge of $2.8M in COGS; production has resumed; # of FDA-licensed plasma centers on track for 10 by year-end.
- Terminated financial advisory agreement with Morgan Stanley; continues to evaluate strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/brhc20057230_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-038803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer